



(51) International Patent Classification:

G01N 33/574 (2006.01) A61K 31/5375 (2006.01)

G01N 33/68 (2006.01) A61K 31/16 (2006.01)

G01N 33/84 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/SG2023/050216

(22) International Filing Date:

30 March 2023 (30.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202250128U 30 May 2022 (30.05.2022) SG

(71) Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way,

#20-10, Connexis North Tower, Singapore 138632 (SG).

SINGAPORE HEALTH SERVICES PTE LTD [SG/SG];

10 Hospital Boulevard, #19-01, Singapore 168582 (SG).

(72) Inventors: SHANMUGAM, Raghuvaram; Institute of

Molecular and Cell Biology, Level 3, VT lab, 61 Biopo-

lis Dr, Proteos, Singapore 138673 (SG); TERGAONKAR,

Vinay Bhimrao Krishna; Institute of Molecular and Cell

Biology, 61 Biopolis Dr #03-15, Proteos, Singapore 138673

(SG). TAN, Iain Bee Huat; National Cancer Centre Sing-

apore, 10 Hospital Boulevard, #19-01, Singapore 168582

(SG). MACALINAO, Dominique Camat; National Can-

cer Centre Singapore, 10 Hospital Boulevard, #19-01, Sin-

apore 168582 (SG). CHONG, Qingqing Dawn; National

Cancer Centre Singapore, 10 Hospital Boulevard, #19-01,

Singapore 168582 (SG).

(74) Agent: DAVIES COLLISON CAVE ASIA PTE. LTD.;

10 Collyer Quay #07-01, Ocean Financial Centre, Singa-

apore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: METHOD OF IDENTIFYING A SUBJECT FOR THERAPY




Figure 6

(57) Abstract: The disclosure relates to methods of treatment and methods of identifying subjects for such treatment based on levels of pirin and/or iron in samples from the subject. In one embodiment, the subject is suffering from cancer, such as colorectal cancer, hemochromatosis or anaemia. In one embodiment, the treatment includes administration of iron chelator or pirin inhibitor.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

04 January 2024 (04.01.2024)